Peptides for Post-COVID Recovery: Immune, Cognitive & Energy Support

Post-COVID syndrome — commonly called long COVID — affects an estimated 10–30% of people who contract SARS-CoV-2, regardless of initial infection severity. The condition involves persistent symptoms lasting months to years after acute infection, most commonly fatigue, cognitive dysfunction ("brain fog"), exercise intolerance, and immune dysregulation.

The pathophysiology is multifactorial: persistent viral reservoirs, autoimmune activation, endothelial dysfunction, microbiome disruption, mitochondrial impairment, and neuroinflammation all contribute. This complexity is precisely why peptides — which can target specific biological pathways — have attracted clinical interest for post-COVID recovery.

This guide evaluates six peptides with mechanistic relevance to long COVID pathology. The evidence ranges from well-characterized immune modulators with approved indications to research-stage compounds with preclinical data only.

Understanding post-COVID pathology

Before evaluating specific peptides, it is important to understand what is happening in long COVID at the biological level, because each peptide addresses different aspects of this pathology.

Immune dysregulation: persistent T-cell exhaustion, elevated inflammatory cytokines (IL-6, TNF-alpha, IFN-gamma), reduced regulatory T-cell function, and in some cases, autoantibody formation against autonomic nervous system receptors or other self-antigens.

Neuroinflammation: microglial activation in the brain, disrupted blood-brain barrier integrity, and neuronal metabolic impairment. This drives the cognitive symptoms — difficulty concentrating, word-finding problems, impaired working memory.

Mitochondrial dysfunction: impaired oxidative phosphorylation, reduced ATP production, increased reactive oxygen species (ROS). This manifests as the characteristic fatigue and exercise intolerance — patients feel exhausted after minimal exertion because their cellular energy machinery is not functioning normally.

Endothelial damage: SARS-CoV-2 enters cells via the ACE2 receptor, which is highly expressed on endothelial cells. Persistent endothelial dysfunction impairs blood flow regulation, oxygen delivery, and vascular repair.

Metabolic disruption: altered glucose metabolism, insulin resistance, and shifts in lipid handling. Some long COVID patients develop metabolic profiles resembling metabolic syndrome.

Thymosin Alpha-1: immune rebalancing

Thymosin Alpha-1 (Ta1) is the most clinically established peptide relevant to post-COVID recovery. It is approved in over 35 countries for hepatitis B and as an immune adjuvant, giving it a level of clinical validation that most research peptides lack.

Mechanism of action

Ta1 acts on dendritic cells and T lymphocytes through Toll-like receptor (TLR) signaling:

• Promotes maturation of immature T cells in the thymus
• Enhances CD4+ and CD8+ T-cell function
• Increases regulatory T-cell (Treg) activity — critical for controlling autoimmune responses
• Modulates Th1/Th2 cytokine balance
• Enhances natural killer (NK) cell activity

Relevance to post-COVID

The immune dysregulation in long COVID — particularly T-cell exhaustion and impaired Treg function — maps directly to Ta1's established mechanism. Rather than broadly stimulating or suppressing immunity, Ta1 promotes immune system reorganization toward normal function.

Published evidence: Ta1 was used clinically during acute COVID-19 in several countries. A retrospective study from Wuhan (Liu et al., 2020) reported that Ta1 treatment was associated with reduced mortality in severe COVID-19 patients and restoration of CD4+ and CD8+ T-cell counts. These studies were not randomized controlled trials, but they demonstrate clinical use in the relevant disease context.

For long COVID specifically: no published RCT exists for Ta1 in post-acute COVID syndrome. The rationale is a direct extrapolation from its established immune-modulatory mechanism and its acute COVID clinical use. Several integrative medicine clinics have reported using Ta1 in long COVID protocols, typically at 1.6 mg SC twice weekly for 8–12 weeks, with reported improvements in energy, immune markers, and symptom scores. These remain anecdotal reports.

Evidence level: approved drug with established mechanism; acute COVID clinical use documented; long COVID application is mechanistic extrapolation plus anecdotal clinical reports.

Monitoring

When using Ta1 for post-COVID immune support:

Test	Purpose	Timing
CBC with differential	Track lymphocyte recovery	Baseline, 4 weeks, 12 weeks
CD4/CD8 ratio	T-cell subset assessment	Baseline, 8 weeks
CRP, ESR	Inflammatory markers	Baseline, 4 weeks, 12 weeks
IL-6 (if available)	Specific inflammation tracking	Baseline, 8 weeks
Autoantibody panel	If autoimmune features present	Baseline, 12 weeks

BPC-157: systemic inflammation and endothelial repair

BPC-157 is primarily known as a tissue-healing peptide, but its relevance to post-COVID recovery extends beyond musculoskeletal repair. Its nitric oxide modulation and anti-inflammatory mechanisms address two core features of long COVID: endothelial dysfunction and systemic inflammation.

Mechanism relevance

Nitric oxide system: BPC-157 modulates the NO/NOS pathway, which is central to endothelial function. In long COVID, impaired NO signaling contributes to vascular dysfunction, reduced tissue perfusion, and exercise intolerance. BPC-157's ability to restore NO system homeostasis — documented across multiple animal injury models — makes it mechanistically relevant.

Anti-inflammatory effects: BPC-157 reduces pro-inflammatory cytokines (TNF-alpha, IL-6) in animal models of systemic inflammation. Long COVID involves persistent elevation of these same cytokines.

Gut-brain axis: BPC-157 originates from a gastric protein and has demonstrated gut-protective effects in multiple animal models. Long COVID frequently involves gut microbiome disruption and increased intestinal permeability ("leaky gut"), which may contribute to systemic inflammation and neuroinflammation via the gut-brain axis.

Practical considerations

BPC-157 for post-COVID recovery is typically used at 250–500 mcg SC daily for 4–8 weeks. Some practitioners use oral BPC-157 when the primary target is gut barrier restoration. The logic is that addressing gut permeability could reduce the systemic inflammatory load driving other symptoms.

Evidence level: strong preclinical data for the relevant mechanisms (NO modulation, anti-inflammatory, gut protection). No human data for post-COVID application. The mechanistic fit is logical but unvalidated in controlled trials.

Selank: anxiety and cognitive restoration

Selank is a synthetic analog of the endogenous immune peptide tuftsin, developed at the Institute of Molecular Genetics (Russian Academy of Sciences). It has anxiolytic and nootropic properties and is approved in Russia for generalized anxiety disorder.

Mechanism of action

• Modulates GABA-A receptor function — producing anxiolytic effects without the sedation or dependence risk of benzodiazepines
• Influences BDNF (brain-derived neurotrophic factor) expression — promoting neuroplasticity and cognitive recovery
• Stabilizes enkephalin degradation — maintaining endogenous opioid peptide levels that regulate mood and stress response
• Modulates IL-6 and other inflammatory cytokines — providing mild anti-inflammatory effects in the CNS

Relevance to post-COVID brain fog

Post-COVID cognitive dysfunction involves neuroinflammation, impaired neuroplasticity, and disrupted neurotransmitter signaling. Selank addresses multiple components:

• GABA modulation helps with the anxiety and emotional dysregulation common in long COVID
• BDNF upregulation supports neuronal recovery and cognitive restoration
• The mild anti-neuroinflammatory effects complement its cognitive benefits
• Unlike stimulants, Selank does not create energy debt — it supports cognitive function without the crash

NA-Selank-Amidate is a modified form with improved metabolic stability and potentially enhanced bioavailability, developed to extend the relatively short half-life of native Selank.

Evidence level: approved anxiolytic in Russia with published human trials for anxiety. Nootropic effects documented in human and animal studies. Application to post-COVID brain fog is mechanistic extrapolation — no published data specifically for long COVID cognitive symptoms.

Common protocol

Selank is typically administered intranasally at 250–500 mcg per nostril, 1–3 times daily. The onset of anxiolytic effects is usually within 15–30 minutes. Cognitive benefits may take 1–2 weeks of consistent use to become apparent.

Semax: neuroprotection and cognitive enhancement

Semax is a synthetic analog of ACTH(4-10), the active fragment of adrenocorticotropic hormone, developed at the same institute as Selank. It is approved in Russia for stroke recovery and cognitive disorders.

Mechanism of action

• Increases BDNF and NGF (nerve growth factor) expression in the brain — directly promoting neuronal survival and growth
• Modulates serotonergic and dopaminergic neurotransmission
• Provides neuroprotective effects against oxidative stress and excitotoxicity
• Has immunomodulatory properties, including effects on inflammatory cytokine expression in brain tissue

Relevance to post-COVID

While Selank is better suited for the anxiety and emotional components of long COVID, Semax targets the core cognitive deficits:

• BDNF/NGF upregulation directly addresses impaired neuroplasticity
• Neuroprotection against oxidative stress is relevant because neuroinflammation generates excessive ROS in brain tissue
• Dopaminergic modulation may help with the motivational deficits and anhedonia reported by many long COVID patients
• Approved use for stroke recovery demonstrates efficacy in post-neurological-insult cognitive rehabilitation

Evidence level: approved in Russia for ischemic stroke and cognitive disorders. Published human studies demonstrate neurotrophic factor upregulation and cognitive improvement in post-stroke patients. Application to post-COVID neuroinflammation is mechanistic extrapolation supported by the neurological indication parallel.

Common protocol

Semax is typically administered intranasally at 200–600 mcg, 2–3 times daily. N-Acetyl Semax Amidate is a modified version with enhanced stability and potency. Cycles of 4–8 weeks are common, often with periodic breaks.

SS-31 (Elamipretide): mitochondrial recovery

SS-31 (also known as elamipretide or Bendavia) targets what may be the central mechanism in long COVID fatigue: mitochondrial dysfunction. It is a tetrapeptide that specifically targets the inner mitochondrial membrane.

Mechanism of action

SS-31 binds to cardiolipin, a phospholipid unique to the inner mitochondrial membrane that is essential for electron transport chain (ETC) function:

• Stabilizes cardiolipin-cytochrome c interactions, optimizing electron transfer
• Reduces mitochondrial ROS production at the source (Complex I and Complex III)
• Preserves mitochondrial membrane potential under stress
• Improves ATP synthesis efficiency without stimulating mitochondrial biogenesis — it makes existing mitochondria work better

Relevance to post-COVID

Mitochondrial dysfunction is increasingly recognized as a central driver of long COVID fatigue and exercise intolerance:

• Post-COVID patients show reduced oxygen extraction and utilization in muscle tissue
• Mitochondrial membrane damage from viral-induced inflammation impairs ETC function
• Excessive ROS production creates a vicious cycle of further mitochondrial damage
• The result is an energy production deficit that manifests as profound fatigue and post-exertional malaise

SS-31 directly addresses this pathway by stabilizing the mitochondrial membrane and restoring ETC efficiency.

Evidence level: SS-31/elamipretide has completed Phase 2 and Phase 3 clinical trials for Barth syndrome (a genetic mitochondrial disorder) and primary mitochondrial myopathy. These trials demonstrated improved exercise tolerance and cardiac function. Application to post-COVID mitochondrial dysfunction is a mechanistic extrapolation from established mitochondrial disease data — the pathology overlap is significant.

Practical considerations

SS-31 is typically used at 10–40 mg SC daily in research protocols. Availability is limited compared to more established peptides. The compound is still in clinical development for its primary indications. Users should be aware that this is a research-stage compound with limited real-world clinical experience outside of controlled trials.

MOTS-c: metabolic recalibration

MOTS-c is a mitochondria-derived peptide (encoded in mitochondrial DNA) that acts as a metabolic regulator. Its relevance to post-COVID recovery centers on metabolic dysfunction — the altered glucose handling, insulin resistance, and energy metabolism disruption seen in many long COVID patients.

Mechanism of action

• Activates AMPK (AMP-activated protein kinase) — the master metabolic sensor that regulates glucose uptake, fatty acid oxidation, and mitochondrial function
• Improves insulin sensitivity and glucose metabolism
• Promotes fatty acid oxidation over glycolysis under metabolic stress
• Acts as a retrograde signal from mitochondria to the nucleus, coordinating metabolic gene expression
• Has exercise-mimetic properties — activating some of the same metabolic pathways triggered by physical exercise

Relevance to post-COVID

Many long COVID patients develop metabolic dysregulation:

• New-onset insulin resistance or worsened glycemic control
• Altered lipid profiles
• Exercise intolerance that prevents the physical activity needed for metabolic recovery
• Impaired cellular energy allocation

MOTS-c's ability to activate AMPK and improve metabolic function independently of exercise is particularly relevant for patients who cannot exercise due to post-exertional malaise. It provides metabolic stimulation without the physical exertion that triggers symptom flares.

Evidence level: MOTS-c has published human data showing metabolic improvements in obese individuals. Its biology is well-characterized from both animal studies and human observational data (MOTS-c levels decline with age and correlate with metabolic health). Application to post-COVID metabolic dysfunction is mechanistic extrapolation. No published study has tested MOTS-c specifically in long COVID patients.

Common protocol

MOTS-c is typically used at 5–10 mg SC, 3–5 times per week for 4–8 weeks. Some protocols cycle with 4 weeks on and 2 weeks off to prevent AMPK pathway desensitization.

Combining peptides for post-COVID recovery

Many practitioners use multi-peptide protocols for long COVID, targeting different pathological mechanisms simultaneously. A typical tiered approach:

Tier 1: Immune foundation

Thymosin Alpha-1 alone, 1.6 mg SC twice weekly for 8–12 weeks. This addresses the upstream immune dysregulation that drives many downstream symptoms. Start here and reassess before adding complexity.

Tier 2: Add symptom-targeted peptides

Based on predominant symptoms:

Primary symptom	Peptide addition	Rationale
Brain fog, cognitive dysfunction	Selank and/or Semax (intranasal)	BDNF upregulation, GABA modulation
Profound fatigue, exercise intolerance	SS-31 (SC)	Mitochondrial ETC optimization
Metabolic disruption, weight changes	MOTS-c (SC)	AMPK activation, insulin sensitization
Gut symptoms, systemic inflammation	BPC-157 (SC or oral)	NO modulation, gut barrier repair

Tier 3: Reassess and adjust

At 8 weeks, reassess symptoms and biomarkers. Discontinue peptides that have achieved their purpose. Continue those addressing persistent deficits. Avoid indefinite polypharmacy — each compound should have a clear target and a defined endpoint.

What the evidence does and does not support

Supported by established mechanism and clinical precedent:

• Thymosin Alpha-1 for immune rebalancing (approved for related indications)
• Selank for anxiety and cognitive support (approved for GAD in Russia)
• Semax for cognitive rehabilitation (approved for stroke recovery in Russia)

Supported by strong mechanism and clinical trial data (not for long COVID specifically):

• SS-31 for mitochondrial dysfunction (Phase 2/3 trials for mitochondrial diseases)
• MOTS-c for metabolic dysfunction (human metabolic studies published)

Supported by preclinical mechanism only:

• BPC-157 for endothelial and gut repair (extensive animal data, no human trials)

Not supported:

• Any claim that peptides "cure" long COVID
• The idea that a single peptide addresses the full spectrum of post-COVID pathology
• Skipping conventional medical evaluation in favor of peptide self-treatment

FAQ

Can peptides cure long COVID?

No peptide cures long COVID. Post-COVID syndrome is a complex, multisystem condition with multiple overlapping pathological mechanisms. Peptides can potentially address specific aspects of the pathology — immune dysregulation, neuroinflammation, mitochondrial dysfunction, metabolic disruption — but they are adjunctive tools, not cures. Comprehensive management typically includes pacing strategies, rehabilitation, sleep optimization, nutritional support, and conventional medical care alongside any peptide protocol.

Which peptide should I try first for post-COVID fatigue?

The answer depends on the underlying driver of fatigue. If immune panels show persistent T-cell dysfunction and elevated inflammatory markers, Thymosin Alpha-1 addresses the upstream cause. If mitochondrial dysfunction is suspected (exercise intolerance, post-exertional malaise), SS-31 or MOTS-c targets energy production directly. A baseline workup including CBC with differential, inflammatory markers (CRP, IL-6), metabolic panel, and ideally T-cell subset analysis helps guide the choice. Starting with immune assessment and Thymosin Alpha-1 is a reasonable default approach given its established clinical profile.

Are Selank and Semax safe to use together?

Selank and Semax have different primary mechanisms (GABA modulation vs. neurotrophic factor upregulation) and are commonly used together in Russian clinical practice for cognitive and neurological conditions. They are generally considered complementary rather than redundant. However, combined nootropic protocols should start with one compound to establish baseline response before adding the second, so you can attribute effects and side effects clearly.

How long before I notice results from post-COVID peptide protocols?

Timelines vary by peptide and symptom target. Selank may produce noticeable anxiolytic effects within days. Cognitive improvements from Semax typically take 1–3 weeks. Immune rebalancing with Thymosin Alpha-1 generally requires 4–8 weeks to manifest clinically. Mitochondrial recovery with SS-31 or MOTS-c may show energy improvements within 2–4 weeks. Full benefit from comprehensive protocols typically requires 8–12 weeks of consistent use.

Should I work with a doctor when using peptides for long COVID?

Yes. Long COVID has significant symptom overlap with other conditions — autoimmune disease, mast cell activation syndrome, autonomic dysfunction, adrenal insufficiency — that require proper diagnosis. Self-treating with peptides without medical evaluation risks missing treatable conditions and creates monitoring blind spots. A physician can order appropriate baseline labs, monitor for adverse effects, adjust concurrent medications, and help determine whether symptom changes reflect peptide benefit or disease progression.

Is BPC-157 oral or injectable better for post-COVID gut symptoms?

For post-COVID gut symptoms specifically, oral BPC-157 has a logical advantage: it delivers the peptide directly to the gastrointestinal mucosa, where gut barrier repair is needed. BPC-157 has unusual gastric acid stability for a peptide, making oral delivery plausible (this has been demonstrated in animal studies). Injectable (SC) BPC-157 may be preferable when systemic anti-inflammatory effects and endothelial repair are the primary goals. Some practitioners use both routes simultaneously for patients with both gut and systemic symptoms.